Literature DB >> 15337407

Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.

C Schmid1, S Nkunku, A Merolle, P Vounatsou, C Burri.   

Abstract

In 2000, we reported that a new short treatment schedule of melarsoprol was not worse than the longer and demanding standard treatment for late-stage human African trypanosomiasis. This alternative schedule was assessed in an open, randomised clinical equivalence trial of 500 patients in Angola. 24 h after treatment, all patients were parasite free. Of 442 patients, 12 (3%) had relapsed after 1 year, of whom seven (3%) had had standard treatment and five (2%) the alternative treatment. After 2 years, 23 (5%) relapsing patients were reported, 11 (5%) in the standard treatment group and 12 (6%) in the new group. The results at the 2-year follow-up support and strengthen our previous findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337407     DOI: 10.1016/S0140-6736(04)16940-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  African Trypanosomiasis: Changing Epidemiology and Consequences.

Authors:  Jean-Paul Chretien; Bonnie L Smoak
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 3.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

Review 4.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Immunobiology of African trypanosomes: need of alternative interventions.

Authors:  Toya Nath Baral
Journal:  J Biomed Biotechnol       Date:  2010-02-23

Review 6.  Chemotherapy for second-stage human African trypanosomiasis.

Authors:  Vittoria Lutje; Jorge Seixas; Adrian Kennedy
Journal:  Cochrane Database Syst Rev       Date:  2013-06-28

7.  Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies.

Authors:  Walter O Inojosa; Inacio Augusto; Zeno Bisoffi; Teofile Josenado; Paulo M Abel; August Stich; Christopher J M Whitty
Journal:  BMJ       Date:  2006-06-15

Review 8.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

9.  Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.

Authors:  Irene Kuepfer; Caecilia Schmid; Mpairwe Allan; Andrew Edielu; Emma P Haary; Abbas Kakembo; Stafford Kibona; Johannes Blum; Christian Burri
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28

10.  Hit-to-lead development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness.

Authors:  Gabriel Navarro; Supchar Chokpaiboon; Geraldine De Muylder; Walter M Bray; Sean C Nisam; James H McKerrow; Khanitha Pudhom; Roger G Linington
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.